Trevor James
In March 2020, it was reported that Israel was close to developing a vaccine for COVID-19. Scientists at the country's Institute for Biological Research were expected to announce the development of a vaccine soon, but it would require many months of trials and experiments before it could be deemed safe and effective. In August 2020, it was announced that human trials of the Israeli-made coronavirus vaccine would begin in mid-October. Israel has since carried out a successful vaccination campaign, using the Pfizer/BioNTech vaccine on its population. Prime Minister Benjamin Netanyahu received the country's first coronavirus inoculation and said that Israel would be the first country to exit the coronavirus crisis.
| Characteristics | Values |
|---|---|
| Vaccine development | Scientists at Israel's Institute for Biological Research have made progress in developing a vaccine for COVID-19. |
| Timeline | As of March 2020, the vaccine was not yet approved and in the early stages of development. In August 2020, human trials were expected to begin in mid-October. |
| Availability | Israel has used the Pfizer/BioNTech vaccine for its population. |
| Booster shots | Israel plans to offer a third dose of the Pfizer/BioNTech vaccine to older citizens. |
| Vaccine distribution | Israel has carried out one of the world's most successful vaccination campaigns. |
| Domestic vaccine availability | The domestic vaccine will first be delivered to Israeli citizens if successful. |
Explore related products
$2.82 $24.95
What You'll Learn
- Israel's Institute for Biological Research is developing a vaccine
- The vaccine was expected to be available within 90 days of testing
- The vaccine was tested on rodents and poultry
- Prime Minister Benjamin Netanyahu received the Pfizer/BioNTech vaccine
- Israel will offer a third COVID-19 shot to older citizens
Israel's Institute for Biological Research is developing a vaccine
Israel's Institute for Biological Research is working on developing a vaccine for COVID-19. The institute is located in the central Israeli town of Nes Tziona and was established in 1952 as part of the Israel Defence Forces' Science Corps. It later became a civilian organization under the supervision of the Prime Minister's Office but maintains close communication with the Defence Ministry.
Scientists at the institute are expected to announce the development of a vaccine for the coronavirus soon. However, it is important to note that this process will require extensive trials and experiments before the vaccine can be deemed safe and effective for human use. Former vaccine evaluator for Israel's Health Ministry, Manfred Green, warned that a proper vaccine development process could take up to 18 months.
The Institute for Biological Research has made significant breakthroughs in understanding the biological mechanism and qualities of the virus, including better diagnostic capabilities and the production of antibodies for those already infected with COVID-19. They have also successfully completed coronavirus vaccine trials on rodents, as reported in June 2020. The institute's director, Prof. Shmuel Shapira, expressed confidence in the potential success of the vaccine, stating that they already have the product in hand and are preparing to begin safety and efficiency tests.
In addition to the efforts of the Institute for Biological Research, Israel has also successfully conducted one of the world's most aggressive and successful vaccination campaigns, primarily utilizing the Pfizer/BioNTech vaccine. Prime Minister Benjamin Netanyahu received the country's first COVID-19 inoculation and has since led the country's rapid vaccination program, aiming to vaccinate 200,000 Israelis per day.
Vaccination Requirements for Visiting New York City
You may want to see also
Explore related products
The vaccine was expected to be available within 90 days of testing
In February 2020, Israeli scientists at the MIGAL Galilee Research Institute announced a breakthrough in developing a vaccine for COVID-19. The rapid progress was attributed to four years of prior research on developing a vaccine for an avian coronavirus affecting poultry that could be adapted to combat other viruses, including COVID-19. The oral vaccine had proven effective against the infectious bronchitis virus (IBV) found in poultry.
Dr. Chen Katz, MIGAL's biotechnology group leader, commented that their basic concept was to develop the technology rather than a vaccine for a specific virus. He stated that they needed to "adjust the system" from the poultry coronavirus to the human one and that they would have a vaccine to prevent coronavirus within a few weeks if successful.
The 90-day timeframe mentioned by MIGAL researchers referred to the period when the vaccine would be ready for human testing rather than production. Officials expected the drug to be available for distribution within 90 days of completing the necessary testing. However, it is important to note that the vaccine development process typically requires a long series of pre-clinical trials on animals followed by clinical trials on humans. This comprehensive process allows for a thorough understanding of side effects and how different populations are affected.
While the MIGAL vaccine had not yet started human trials as of August 2020, the institute was preparing to manufacture 10 to 15 million doses. They had also completed successful coronavirus vaccine trials on rodents, publishing a paper on the bioRxiv website. In the paper, researchers expressed hope for a finished vaccine within a year or possibly sooner.
It is worth noting that the standard vaccine development process can be accelerated during a global health emergency to vaccinate those most at risk from the virus. However, rushing this process can be "very risky," according to Manfred Green, a former vaccine evaluator for Israel's Health Ministry. He warned that a proper vaccine development process could take up to 18 months.
Inoculation: Training Our Bodies to Fight Diseases
You may want to see also
Explore related products
$20.99 $25.48
The vaccine was tested on rodents and poultry
Israel has been at the forefront of developing a vaccine for COVID-19. Scientists at the country's Institute for Biological Research, a civilian organization formerly under the Defense Ministry, have been working on developing a vaccine for COVID-19. While there have been reports of breakthroughs in developing a vaccine, it is important to note that the process of vaccine development requires rigorous testing and experimentation.
The vaccine development process typically includes pre-clinical trials on animals, such as rodents and poultry, followed by clinical trials on humans. This iterative process allows for a comprehensive understanding of side effects and how different populations are affected. In June 2020, the Institute for Biological Research announced successful coronavirus vaccine trials on rodents, specifically hamsters. The researchers reported that their vaccine "results in rapid and potent induction of neutralizing antibodies".
The state-funded Migal Galilee Research Institute also announced a breakthrough in March 2020. They credited their rapid progress to four years of previous research focused on developing a vaccine for an avian coronavirus affecting poultry. The research team leader clarified that their 90-day timeframe referred to the point when the product would be ready for human testing rather than mass production. This timeline was echoed by officials who expected the drug to be available within 90 days after completing the necessary testing.
The oral vaccine developed by MIGAL scientists was tested at the Veterinary Institute and proven effective in inducing high levels of specific anti-IBV antibodies. They believed that by adjusting the system from the poultry coronavirus to the human one, they would soon have a vaccine to prevent coronavirus. However, it is important to approach such claims with caution, as vaccine development typically requires a lengthy and meticulous process to ensure safety and effectiveness.
Putin's Daughter: Vaccine Victim or Conspiracy Theory?
You may want to see also
Explore related products
Prime Minister Benjamin Netanyahu received the Pfizer/BioNTech vaccine
Israeli Prime Minister Benjamin Netanyahu received the Pfizer/BioNTech vaccine on December 19, 2020, at Sheba Hospital in Tel Aviv. He is the first Israeli and the first sitting prime minister publicly known to receive the Pfizer/BioNTech vaccine. Netanyahu's vaccination was shown live on Israeli television.
Netanyahu said he was excited and proud to be the Prime Minister of Israel, and that the vaccine was a small injection for man, a giant leap for our health. He also said that he thought about reopening the country and returning to normalcy. In a video on his official Facebook page, Netanyahu showed off the syringe that gave him the COVID-19 vaccine, and said that Israel will be the first country to exit the coronavirus crisis.
Netanyahu's vaccination was part of an Israeli inoculation campaign that began on December 19, 2020. More than a million Israelis have since received the first dose of the Pfizer-BioNTech vaccine. The Israeli healthcare system's success in vaccinating more than 10% of the population in a brief period garnered widespread international acclaim and extensive press attention.
Vaccine Differences: France and the US
You may want to see also
Explore related products
Israel will offer a third COVID-19 shot to older citizens
In March 2020, a social media image claimed that a vaccine for COVID-19 had been approved in Israel and was being mass-produced. This was false. While Israeli scientists are working on developing a vaccine, such a vaccine is not yet approved, and it will not be ready for distribution in the near future.
In August 2020, it was reported that human trials of an Israeli-made coronavirus vaccine would begin in mid-October. The director of the Institute for Biological Research, Prof. Shmuel Shapira, expressed confidence in the vaccine's success. However, a vaccine adviser to the government cautioned that there was no guarantee that the shots being developed would be widely effective.
Israel has since approved and administered vaccines to its citizens, with Prime Minister Benjamin Netanyahu receiving the country's first coronavirus inoculation, a dose of the Pfizer/BioNTech vaccine. Over 57% of Israel's citizens have received two doses of the Pfizer/BioNTech vaccine, and over 80% of the population over 40 is vaccinated. This allowed Israel to reopen its economy ahead of other countries. However, Israel has seen a spike in cases of the new delta variant, even among vaccinated individuals.
To address this issue, Israel has announced that it will offer a third COVID-19 booster shot to people over 60 who have already been vaccinated. This decision comes amid rising infections and evidence that the vaccine's efficacy wanes over time. Prime Minister Naftali Bennett stated that a team of expert advisers overwhelmingly agreed that launching the booster campaign made sense based on considerable research and analysis. This makes Israel the first country to offer a third dose of a Western vaccine to its citizens on a wide scale.
Vaccinations: Training Our Adaptive Immune Response
You may want to see also
Frequently asked questions
Yes, Israel has administered at least one dose of the Pfizer/BioNTech vaccine to more than half of its 9.3 million people.
Israel has administered at least one dose to more than half its population of 9.3 million people and the required two doses to about one-third.
Israel used the Pfizer/BioNTech vaccine.
